Table 6 Economic analysis results in 2013 United States dollars for IPV5 compared to both reference cases (RCs) involving continued OPV use
From: An economic analysis of poliovirus risk management policy options for 2013–2052
Income level | Discounted, cumulative vaccination costs ($ billions) | Discounted, cumulative paralytic polio cases | Incremental costs ($ billions) | Paralytic polio cases prevented | Incremental cost-effectiveness ratio (ICER) | Incremental net benefits (INBs) ($ billions) | |||
|---|---|---|---|---|---|---|---|---|---|
IPV5 | Reference case | IPV5 | Reference case | Per paralytic polio case prevented ($/case) | Per DALY averted ($/DALY) | ||||
IPV5 vs. RC no SIAs and OPV restart without SIAs | |||||||||
LOW | 2.9 | 3.9 | 2,700 | 420,00 | −1.2 | 420,000 | CLS | CLS | 4.7 |
LMI | 6.1 | 7.4 | 3,700 | 350,00 | −3.6 | 350,000 | CLS | CLS | 15 |
UMI | 12 | 8.1 | 150 | 1,200 | 3.7 | 1,000 | 3,600,000 | 250,000 | −3.5 |
HIGH | 16 | 15 | 3 | 8 | 0.4 | 5 | 80,000,000 | 5,600,000 | −0.4 |
World | 37 | 35 | 6,500 | 770,000 | −0.6 | 770,000 | N/A | N/A | 16 |
IPV5 vs. RC with SIAs and OPV restart with SIAs | |||||||||
LOW | 2.9 | 8.9 | 1,400 | 1,500 | −6.0 | 180 | CLS | CLS | 6.0 |
LMI | 6.1 | 18 | 2,400 | 2,400 | −12 | −48 | CSLC | CSLC | 12 |
UMI | 12 | 11 | 150 | 920 | 0.7 | 780 | 870,000 | 62,000 | −0.5 |
HIGH | 16 | 16 | 3 | 8 | 0.2 | 5 | 41,000,000 | 2,900,000 | −0.2 |
World | 37 | 53 | 3,900 | 4,800 | −17 | 910 | N/A | N/A | 17 |